We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Napo Pharm.Regs | LSE:NAPL | London | Ordinary Share | COM USD0.0001 REGS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.35 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
10/5/2008 14:59 | TDW closed at 9p-11p !! | flojo | |
09/5/2008 17:00 | flojo - I think we can safely say that they are probably short of stock considering each 5000 buy moves the price up, wait til they have sustained buying lets see what happens then! Of cause a bigger buy may get reported on Monday or Tuesday. | monis | |
09/5/2008 16:47 | Just spoke to tdw,the 5000 mm is on 9p sell 11p buy!! | flojo | |
09/5/2008 16:43 | Dont know ,im went with tdwaterhouse fill or kill @ 10p.i will ring tdw. | flojo | |
09/5/2008 16:35 | Flojo- How do you mean they would have none of it? How can they refuse to sell if it's within the limits which 5000 is? Was it because they were in Auction perhaps? | monis | |
09/5/2008 16:32 | Tried to buy 5000 at around 4 pm would have none of it,how did the other 5000 gp through ? | flojo | |
09/5/2008 16:05 | Up again. Also just gone into Auction I would guess another big buy will be reported just before close. | monis | |
09/5/2008 10:19 | More info. What is interesting is that it was only in March of this year that they announced the following. ...The Company is also raising approximately $0.3 million by issuing 600,000 common shares by way of the Subscription at 25 pence, which represents a 7.4 per cent discount to the closing mid-price of the common shares on 5 March 2008. You would presume that the investor must be confident of a commercial partner for Napo and CRO-HIV. All the indications since are that the results have been underestimated. The more I research the company the more immediate upside to it I see. Still ridiculously cheap imho. DYOR. | monis | |
08/5/2008 15:48 | Having done further research for anyone interested, If the late-stage Phase 3 program, CRO-HIV for AIDS diarrhea is a success(obviously still a risk)the revenues according to the annual report would be vast. DYOR under the market section in the report on the website. With the directors having recently stated that previous good results have been ignored by the market all indications are that it has a good chance. Of cause do your own research but these to me look hugely undervalued. | monis | |
08/5/2008 15:29 | I think they are walking it back up in anticipation of a partnership deal but maybe wrong. If they do phase 3 and it is succesful there is little doubt that the potential revenues are vast. Risk/reward. Of cause do your own research. | monis | |
08/5/2008 15:22 | From recent update. Make of it what you will. ...Management have plans to raise additional funds, which include: the out-license of certain rights to crofelemer including the indications of CRO-HIV, CRO-IBS,CRO-ID and CRO-PED in the United States and other western territories; as well as certain rights to NP-500, in exchange for a licensing fee(s)... ...Sir William Young, Chairman of the Board of Napo commented: "While Napo needs to bring in funds from corporate partnering and other activities in order to complete its Phase 3 trial, the board feels the recent stock price drop dramatically undervalues the company." ... Lisa A. Conte CEO of Napo Pharmaceuticals, Inc. commented: "It is my firm belief that, the fall in the Company's share price places an unrealistic value on Napo and disregards the recently announced trial results. Of cause DYOR. | monis | |
08/5/2008 15:09 | guys wots the take here is this going to keep going ,loking to dabble | cliffbarns2 | |
08/5/2008 15:00 | 30,000 buy at 10p reported. | monis | |
08/5/2008 12:45 | Still says Auction on Level 2. I may be wrong but I think there is another big buy in the wings either that or they are just walking it right back up again. DYOR | monis | |
08/5/2008 12:23 | Does anybody have the facility to know if there is another big buy order in? | monis | |
08/5/2008 12:11 | Still can't buy on line. | monis | |
08/5/2008 11:57 | And up again. | monis | |
08/5/2008 11:54 | Up again. Can't buy any online. | monis | |
08/5/2008 11:36 | Still says Auction. | monis | |
08/5/2008 11:21 | On L2 it has come up as Auction. | monis | |
08/5/2008 11:19 | Monis what does AU mean ? | flojo | |
08/5/2008 11:11 | It's now gone to Auction. | monis | |
08/5/2008 10:52 | 21 April 2008 Sir William Young, Chairman of the Board of Napo commented: "While Napo needs to bring in funds from corporate partnering and other activities in order to complete its Phase 3 trial, the board feels the recent stock price drop dramatically undervalues the company." Lisa A. Conte CEO of Napo Pharmaceuticals, Inc. commented: "It is my firm belief that, the fall in the Company's share price places an unrealistic value on Napo and disregards the recently announced trial results. The statistically significant results on crofelemer in the treatment of acute infectious diarrhoea have infused our on-going corporate partner and grant discussions with the opportunity to represent a potential dual indication approach to filings for regulatory approvals for crofelemer next year-chronic diarrhoea in people living with HIV/AIDS and acute infectious diarrhoea. This approach may potentially increase the likelihood of regulatory approval for at least one indication of crofelemer, it may also expand the available patient populations that might benefit from crofelemer, as well as increasing the target market size." | monis | |
08/5/2008 10:30 | Having done further research for anyone interested, If the late-stage Phase 3 program, CRO-HIV for AIDS diarrhea is a success(obviously still a risk)the revenues according to the annual report would be vast. DYOR under the market section in the report on the website. With the directors having recently stated that previous good results have been ignored by the market all indication are that it has a good chance. Of cause do your own research but these to me look hugely undervalued. | monis | |
08/5/2008 09:58 | Up again. Share awards seem to me to state that directors don't get the shares unless the share price reaches $3.50 that is about a 1 pound seventy share price. So huge potential upside still. Of cause DYOR. It now just 9p! | monis |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions